At the Rheumatology Research Institute that bears his name, Professor Evgeniy Nasonov, a respected member of the Russian Academy of Sciences, is recognized for leading pioneering work in the field. He serves as scientific director of the institute and chairs the All-Russian public organization “Russian Union of Rheumatologists.” His contributions have helped shape a broader understanding of arthritis treatment within the medical community and beyond.
“This is a field we now call regenerative medicine,” Nasonov explained. “It includes mesenchymal stem cell therapy as one clear avenue. Another approach involves harvesting a patient’s own cells, activating the FOXP3+ protein, and then reintroducing these cells to the body. Through this process, the goal is to restore immune tolerance and dampen inflammatory activity, which can reduce tissue damage over time.”
FOXP3+ refers to a protein that plays a central role in the function of regulatory T cells, or Tregs, which help keep inflammation under control. When FOXP3+ activity weakens, immune cells may become misdirected, increasing the risk that they attack healthy tissues. This nuance sits at the heart of discussions about how to recalibrate the immune system in chronic inflammatory diseases like arthritis.
“It is important to note that these approaches are at early stages of testing,” the expert cautioned. “They hold promise, but more research is needed before they can be recommended as standard clinical practice.”
There is growing interest in a wider spectrum of arthritis treatments, including various cellular and immune-modulating strategies. Further examination of regenerative therapies and their potential roles is ongoing, with researchers and clinicians watching for robust evidence and long-term outcomes (citation: socialbites.ca).
Earlier statements by the same academician highlighted that certain treatments could stand out for arthritis management, underscoring the evolving landscape of care and the continuous search for options that improve patient outcomes.